EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieVergleichsstudie

Endovascular Treatment Versus Hybrid Repair for Iliofemoral Occlusive Disease: A Pilot Prospective Randomized Trial

Shoraan Saaya iD, Vsevolod Akulov iD, Alexander Gostev iD, Aleksey Cheban iD, Olesya Osipova iD, Pavel Ignatenko iD, Vladimir Starodubtsev iD, Yann Gouëffic iD, Andrey Karpenko iD, A M Chernyavskiy iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31649 ↗

At a glance

Randomisierte kontrollierte Studie in Catheterization and Cardiovascular Interventions, 2025. Written by Shoraan Saaya and 9 co-authors. Institution: Meshalkin National Medical Research Center, Novosibirsk, Russian Federation. Major MEDLINE topics: Femoral Artery, Iliac Artery, Angioplasty, Balloon, Arterial Occlusive Diseases. Cited 1 times so far (Crossref); 22 references. Funded by: The study was registered on the ClinicalTrials.gov register (Identifier: NCT03315884) and was approved by the Local Ethics Committee of the National Medical Re….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The treatment of patients with a simultaneous lesion of the iliac and common femoral arteries presents a significant challenge.

Aim

The objective of pilot randomized trial (ClinicalTrials.gov) was to compare the short and 3‐year safety and efficacy of endovascular treatment (EVT) and hybrid repair (HR) procedures with using an interwoven nitinol stent for patients with coexisting iliac and common femoral occlusive disease. Materials and Methods In the EVT group patients after recanalization and balloon angioplasty iliac and common femoral arteries were treated with interwoven nitinol stents. In the HR group, patients underwent recanalization and stenting of iliac arteries as in the EVT group but endarterectomy and patch angioplasty for the common femoral artery. Perioperative 1, 2, and 3‐year outcomes were compared between both groups.

Results

Totally 62 patients were randomized (31 EVT and 31 HR). The average hospital length of stay was shorter in EVT group (3.9 ± 1.2 days EVT group vs. 7.9 ± 2.7 days HR group, p = 0.001). There were no mortalities, no MACEs in either group within 30 days post‐op. Thirty‐day perioperative morbidity rate was 9.7% in EVT group versus 22.6% in HR group ( p = 0.17). The primary patency rate at 12, 24 and 36 months was 81%, 60%, and 46% in the EVT group, 94%, 80%, and 73% in the HR group ( p = 0.12, p = 0.09, and p = 0.03). The secondary patency rates at 36 months in EVT group was 83% versus 87% in HR group, respectively ( p = 0.64). Survival and limb salvage rates did not differ between groups at 36 months of follow‐up (93% vs. 93% p = 0.97% and 97% vs. 100% p = 0.31 respectively).

Conclusions

This study supports that the hybrid treatment has an advantage over EVT in terms of safety and primary patency in the mid‐term follow‐up period. However, a larger study is needed to confirm these findings and further investigate the long‐term effects of the hybrid approach.

Subjects

MeSH terms (MEDLINE)

Femoral ArteryIliac ArteryAngioplasty, BalloonArterial Occlusive DiseasesEndarterectomyPeripheral Arterial DiseaseEndovascular ProceduresHumansPilot ProjectsMaleFemaleTreatment OutcomeProspective StudiesStentsAgedTime FactorsVascular PatencyMiddle AgedAlloysLength of StayConstriction, PathologicProsthesis DesignLimb Salvage

Author keywords

atherosclerosisendarterectomyendovascular therapyvascular surgery

Substances

nitinolAlloys

Authors and institutions

  • Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.
  • Laboratoire De Physiopathologie De La Résorption Osseuse, Nantes, France.
  • Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russian Federation.

ORCID profiles: Shoraan Saaya, Vsevolod Akulov, Alexander Gostev, Aleksey Cheban, Olesya Osipova, Pavel Ignatenko, Vladimir Starodubtsev, Yann Gouëffic, Andrey Karpenko, A M Chernyavskiy

Funding

  • The study was registered on the ClinicalTrials.gov register (Identifier: NCT03315884) and was approved by the Local Ethics Committee of the National Medical Re…

Cite

APA

Saaya, S., Akulov, V., Gostev, A., Cheban, A., Osipova, O., Ignatenko, P., Starodubtsev, V., Gouëffic, Y., Karpenko, A., & Chernyavskiy, A. M. (2025). Endovascular Treatment Versus Hybrid Repair for Iliofemoral Occlusive Disease: A Pilot Prospective Randomized Trial. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31649

Vancouver

Saaya S, Akulov V, Gostev A, Cheban A, Osipova O, Ignatenko P, et al. Endovascular Treatment Versus Hybrid Repair for Iliofemoral Occlusive Disease: A Pilot Prospective Randomized Trial. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31649

BibTeX
@article{Saaya2025,
  author = {Saaya, Shoraan and Akulov, Vsevolod and Gostev, Alexander and Cheban, Aleksey and Osipova, Olesya and Ignatenko, Pavel and Starodubtsev, Vladimir and Gouëffic, Yann and Karpenko, Andrey and Chernyavskiy, A M},
  title = {Endovascular Treatment Versus Hybrid Repair for Iliofemoral Occlusive Disease: A Pilot Prospective Randomized Trial},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31649}
}
Start for free →